Advertisement

Annals of Hematology

, Volume 96, Issue 3, pp 449–459 | Cite as

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

  • Ariana Berenson
  • Suzie Vardanyan
  • Michael David
  • James Wang
  • Nika Manik Harutyunyan
  • Jillian Gottlieb
  • Ran Halleluyan
  • Tanya M. Spektor
  • Kyle A. Udd
  • Shahrooz Eshaghian
  • Youram Nassir
  • Benjamin Eades
  • Regina Swift
  • James R. BerensonEmail author
Original Article

Abstract

New classes of drugs including the proteasome inhibitors (PI) bortezomib and, more recently, carfilzomib and the immunomodulatory agent lenalidomide have shown improved outcomes for multiple myeloma (MM) patients during the past decade. However, most of the studies reporting outcomes for patients receiving these drugs have relied on older data sets derived from large institutions that included patients not receiving their treatment at those facilities and represented only those eligible for clinical trials or were from sites where treatment options were limited. We have analyzed data from 258 MM patients who have received treatment with at least one of three agents: bortezomib, carfilzomib, and lenalidomide in a single clinic specializing in MM with respect to their responses and other outcomes to treatment regimens including these agents. Response rates were similar between these three drugs when used for the first time and again during subsequent treatment regimens. As expected, the clinical benefit rates (CBRs) were better for patients receiving their first treatment when compared to their use in subsequent treatment regimens. The CBRs were similar during their 2nd, 3rd, and 4th treatments containing these agents. Many patients refractory to these agents showed responses to regimens containing these same drugs when used in different combinations. In addition, patients refractory to one PI often responded to the other PI. The results of this study demonstrate that novel agents can be used repeatedly in novel combinations with significant clinical benefit for patients with MM.

Keywords

Multiple myeloma Bortezomib, lenalidomide Carfilzomib Overall survival 

Notes

Compliance with ethical standards

Informed consent was obtained from all individual participants included in the study, which was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

Dr. Berenson is a consultant and receives honoraria and research funding from Takeda, Onyx-Amgen, Amgen, Janssen, Celgene, and Bristol-Meyers Squibb. Ms. Swift receives honoraria from Celgene, Takeda, Bristol-Meyers-Squibb, and Onyx-Amgen.

Supplementary material

277_2016_2889_MOESM1_ESM.docx (22 kb)
Supplemental Table 1: Combination Regimens included in Frontline Therapies. (DOCX 21 kb)
277_2016_2889_MOESM2_ESM.docx (22 kb)
Supplemental Table 2: Combination Regimens included in the Salvage Therapies. (DOCX 22 kb)

References

  1. 1.
    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014(15):e538–e548. doi: 10.1016/S1470-2045(14)70442-5 CrossRefGoogle Scholar
  2. 2.
    Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060. doi: 10.1056/NEJMra1011442 CrossRefPubMedGoogle Scholar
  3. 3.
    Nooka AK, Kastritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125:3085–3099. doi: 10.1182/blood-2014-11-568923 CrossRefPubMedGoogle Scholar
  4. 4.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520. doi: 10.1182/blood-2007-10-116129 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rajkumar SV, Kumar S (2015) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 91:101–119. doi: 10.1016/j.mayocp.2015.007 CrossRefGoogle Scholar
  6. 6.
    Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649–659. doi: 10.1111/bjh.12198 CrossRefPubMedGoogle Scholar
  7. 7.
    Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679–686. doi: 10.1182/blood-2010-02-268862 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R (2015) Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. Am J Hematol 90:1106–1110. doi: 10.1002/ajh.24181 CrossRefPubMedGoogle Scholar
  9. 9.
    Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Biesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142–152. doi: 10.1056/NEJMoa1411321 CrossRefPubMedGoogle Scholar
  10. 10.
    Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149–157. doi: 10.1038/leu.2011.196 CrossRefPubMedGoogle Scholar
  11. 11.
    Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473. doi: 10.1038/sj.leu.2404284 CrossRefPubMedGoogle Scholar
  12. 12.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420. doi: 10.1200/JCO.2005.04.242 CrossRefPubMedGoogle Scholar
  13. 13.
    Rajkumar SV, Gahrton G, Bergsagel PL (2007) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118(12):3205–3211. doi: 10.1182/blood-2011-06-297853 CrossRefGoogle Scholar
  14. 14.
    Rajan AM, Rajkumar SV (2015) Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer Journal 5:e365. doi: 10.1038/bcj.2015.92 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Curran MP, McKeage K (2009) Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69:859–888. doi: 10.2165/00003495-200969070-00006 CrossRefPubMedGoogle Scholar
  16. 16.
    Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li ZW, Chen H, Berenson JR (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 148:569–581. doi: 10.1111/j.1365-2141.2009.08008.x CrossRefPubMedGoogle Scholar
  17. 17.
    Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift RA, Vescio RA (2014) Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 28:1529–1536. doi: 10.1038/leu.2014.27 CrossRefPubMedGoogle Scholar
  18. 18.
    Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa A-M, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar SK, Touzeau C, Buadl F, Laubach JP, Lin J, Berg D, DiBacco A, Hui A-M, Richardson PG (2015) Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). Blood 126, Abstract 727 (American Society of Hematology Annual Meeting Abstracts)Google Scholar
  19. 19.
    Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Investigators ASPIRE (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142–152. doi: 10.1056/NEJMoa1411321 CrossRefPubMedGoogle Scholar
  20. 20.
    Berenson J, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam MS, Eshaghian S, Nassir Y, Swift RA, Wang J, Eades B, Spektor TM, Vescio R (2015) A phase 1/2 trial of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma (RRMM). Blood 126, Abstract 5383 (American Society of Hematology Annual Meeting Abstracts)Google Scholar
  21. 21.
    Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG (2015) Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126:2284–2290. doi: 10.1182/blood-2015-05-643320 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ariana Berenson
    • 1
  • Suzie Vardanyan
    • 1
  • Michael David
    • 1
  • James Wang
    • 1
    • 2
  • Nika Manik Harutyunyan
    • 1
  • Jillian Gottlieb
    • 1
  • Ran Halleluyan
    • 1
  • Tanya M. Spektor
    • 3
  • Kyle A. Udd
    • 1
    • 2
  • Shahrooz Eshaghian
    • 1
  • Youram Nassir
    • 2
  • Benjamin Eades
    • 2
  • Regina Swift
    • 2
  • James R. Berenson
    • 1
    • 2
    • 3
    Email author
  1. 1.Institute for Myeloma & Bone Cancer ResearchWest HollywoodUSA
  2. 2.James R. Berenson, MD, Inc.West HollywoodUSA
  3. 3.OncotherapeuticWest HollywoodUSA

Personalised recommendations